Trial Profile
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD; #2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 05 Dec 2018 Status changed from recruiting to completed.
- 22 Jun 2018 Planned number of patients changed from 250 to 500.
- 22 Jun 2018 Planned End Date changed from 1 Oct 2018 to 1 Feb 2019.